Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital

D. Boral Capital analyst Jason Kolbert initiated coverage of Lineage Cell Therapeutics (LCTX) with a Buy rating and $3 price target Lineage is a clinical-stage biotechnology company that specializes in developing innovative cell therapies aimed at treating degenerative diseases, the analyst tells investors in a research note. The firm says the company has a partnership with Roche, focusing on the development and commercialization of OpRegen.